Clone:
BB27
Type of antibody:
Primary antibodies
Isotype:
mouse IgG1κ
Applications:
FC, MICS, IF, IHC, ICC
Alternative names:
EWI-101, IGSF2, V7, p126

Extended validation for CD101 Antibody, anti-human

Specificity

Epitope competition
In order to compare the epitope specificity of an antibody, the clone being used is compared with other known clones recognizing the same antigen in a competition assay.
Other clonesOverlap in epitope recognition with BB27
REA954++
V7.1-
Cells were incubated with an excess of purified unconjugated CD101 (BB27) antibody followed by staining with fluorochrome-conjugated antibodies of other known clones against the same marker. Based on the fluorescence signal obtained, the clones were identified as recognizing completely overlapping (++), partially overlapping (+), or completely different epitopes (-) of the marker.

Sensitivity

Performance comparison
Selected fluorochrome conjugated antibodies from Miltenyi Biotec were compared to commercially available hybridoma clones in flow cytometry analysis.
View details
Flow cytometric comparison of different clones for CD101. Human peripheral blood mononuclear cells (PBMCs) were stained with CD101 antibodies and with a suitable counterstaining. As a control, CD101 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD101. Human peripheral blood mononuclear cells (PBMCs) were stained with CD101 antibodies and with a suitable counterstaining. As a control, CD101 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD101. Human peripheral blood mononuclear cells (PBMCs) were stained with CD101 antibodies and with a suitable counterstaining. As a control, CD101 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD101. Human peripheral blood mononuclear cells (PBMCs) were stained with CD101 antibodies and with a suitable counterstaining. As a control, CD101 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
View details
Flow cytometric comparison of different clones for CD101. Human peripheral blood mononuclear cells (PBMCs) were stained with CD101 antibodies and with a suitable counterstaining. As a control, CD101 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Flow cytometric comparison of different clones for CD101. Human peripheral blood mononuclear cells (PBMCs) were stained with CD101 antibodies and with a suitable counterstaining. As a control, CD101 antibody staining was omitted and cells were measured in the same channels. Flow cytometry was performed with the MACSQuant® Analyzer. Cell debris, dead cells, and cell doublets were excluded from the analysis based on scatter signals and 4',6-diamidino-2-phenylindole (DAPI) fluorescence. No FcR Blocking Reagent was used. The recommended titers of respective antibodies from different suppliers were used.
Fixation data
To provide an indication on how an antibody performs after fixation of cells, in-house data on staining results before and after fixation with 3.7% formaldehyde using Miltenyi Biotec antibodies are provided. Different experimental settings may lead to different results.
No fixation
Post fixation
View details
Comparison of staining pattern on non-fixed and fixed cells using CD101 (BB27). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
View details
Comparison of staining pattern on non-fixed and fixed cells using CD101 (BB27). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.
Comparison of staining pattern on non-fixed and fixed cells using CD101 (BB27). The performance of the antibody after fixation was tested by comparing the staining pattern on fresh (no fixation) versus fixed (post fixation) cells.

Specifications for CD101 Antibody, anti-human

Overview

Clone BB27 recognizes the CD101 antigen, also known as V7 or IGSF2, which is a 140 kDa type I transmembrane glycoprotein of the Ig gene superfamily. CD101 is expressed on monocytes, granulocytes, and subsets of dendritic cells (DCs). In addition, CD101 is expressed on certain subpopulations of T cells, in particular about 5–30% of FoxP3
+
Treg cells in peripheral blood.
The interaction of CD101 with the antibody BB27 has been shown to inhibit T cell activation by allogeneic DCs or CD3 antibodies.

Alternative names

EWI-101, IGSF2, V7, p126

Detailed product information

Technical specifications

CloneBB27
Clonalitymonoclonal
Isotypemouse IgG1κ
Isotype controlIsotype Control Antibody, mouse IgG1
Hostmouse
Type of antibodyPrimary antibodies
Specieshuman
AntigenCD101
Alternative names of antigenEWI-101, IGSF2, V7, p126
Molecular mass of antigen [kDa]113
Distribution of antigendendritic cells, granulocytes, Langerhans cells, monocytes, red blood cells, T cells, lymphocytes, leukemia cells, thymocytes, lung, small intestine, spleen
Entrez Gene ID9398
RRIDAB_2661056, AB_10827694, AB_10829614, AB_2661057, AB_2661058, AB_10828923, AB_2661055

Resources for CD101 Antibody, anti-human

Certificates

Please follow this
link
to search for Certificates of Analysis (CoA) by lot number.

References for CD101 Antibody, anti-human

Publications

  1. Rivas, A. et al. (1995) V7, a novel leukocyte surface protein that participates in T cell activation. J. Immunol. 154: 4423-4433
  2. Soares, L. R. et al. (1998)
    V7 (CD101) ligation inhibits TCR/CD3-induced IL-2 production by blocking Ca
    2+
    flux and nuclear factor of activated T cell nucleartranslocation.
    J. Immunol. 161: 209-217
  3. Bouloc, A. et al. (2000) Triggering CD101 molecule on human cutaneous dendritic cells inhibits T cell proliferation via IL-10 production. Eur. J. Immunol. 30: 3132-3139
  4. Bagot, M. et al. (1997) CD101 is expressed by skin dendritic cells: role in T-lymphocyte activation. Tissue Antigens 50: 439-448

Related products for
CD101 Antibody, anti-human

3 products available

Seems like you are coming from USA!
Do you want to visit our website in your country?